year 19, Issue 73 (3-2020)
J. Med. Plants 2020, 19(73): 27-36 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Iranzadasl M, Mansouri P, Kamalinejad M, Gorji N. Review of skin cancers terminology, etiology and treatment from ancient Persian medicine view point. J. Med. Plants 2020; 19 (73) :27-36
URL: http://jmp.ir/article-1-2472-en.html
URL: http://jmp.ir/article-1-2472-en.html
1- Traditional Persian Medicine, School of Medicine, Shahed University, Tehran, Iran
2- Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran , mansouripr@yahoo.com
3- School of Pharmacy, Shaheed Beheshti University of Medical Sciences, Tehran, Iran
4- Traditional Medicine and History of Medical Sciences Research Center, Institute of Health, Babol University of Medical Science, Babol, Iran
2- Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran , mansouripr@yahoo.com
3- School of Pharmacy, Shaheed Beheshti University of Medical Sciences, Tehran, Iran
4- Traditional Medicine and History of Medical Sciences Research Center, Institute of Health, Babol University of Medical Science, Babol, Iran
Abstract: (2664 Views)
Background: Skin cancers are the most prevalent type among the white with an increasing trend of incidence around the world and Iran. Scientific developments in diagnosing these cancers and using screening methods and utilizing treatment methods have contributed to the relative control of the cancer. Hence, it is necessary to consider other suggested approaches of complementary and traditional medicine to prevent and treat these cancers. Objective: The purpose of this review is to investigate the alternative remedies from the Persian Medicine; as a pioneer medical approach with an old history. Methods: In this review study, the medical textbooks of the golden era of Persian Medicine (9th to 19th centuries AD), i.e., the times of Razes and Avicenna, were explored and interesting opinions on skin malignancies were found. In addition, the phrase “skin cancers” was searched in databases like PubMed, Science Direct, Scopus, and Google Scholar. The gleaned data were analyzed and compared. Results: The ancient Persian scholars knew the cancers and were forerunners in the description, classified, etiology and treatment of skin cancers. This study explored interesting opinions like nutrition and black bile clearance on skin malignancies treatment, also found no contradictory views between the Persian and modern medicine on the topic of skin cancers. Conclusion: Paying attention to the neglected areas can makes useful theories and hypotheses fore achievement to new more effective and safe remedies.
Type of Study: Review |
Subject:
Traditional Pharmacy & Traditional Medicine
Received: 2019/02/28 | Accepted: 2019/03/5 | Published: 2020/06/6
Received: 2019/02/28 | Accepted: 2019/03/5 | Published: 2020/06/6
References
1. Leiter U, Eigentler T, Garbe C. Epidemiology of skin cancer. Advances in Experimental Medicine and Biology 2014; 810:120-40. [DOI:10.1007/978-1-4939-0437-2_7]
2. Gladfelter P, Darwish NH and Mousa SA. Current status and future direction in the management of malignant melanoma. Melanoma Res. 2017; 27 (5): 403-10. [DOI:10.1097/CMR.0000000000000379]
3. Ma C and Armstrong AW. Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2. Journal of Dermatological Treatment 2014; 25 (5): 401-8. [DOI:10.3109/09546634.2013.813897]
4. Menaa F. Latest approved therapies for metastatic melanoma: what comes next? Journal of Skin Cancer. 2013; 2013. [DOI:10.1155/2013/735282]
5. Menzies AM and Long GV. Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond. European J. Cancer (Oxford, England: 1990). 2013; 49 (15): 3229-41. [DOI:10.1016/j.ejca.2013.06.027]
6. Mao JJ, Palmer CS, Healy KE, Desai K and Amsterdam J. Complementary and alternative medicine use among cancer survivors: a population-based study. J. Cancer Survivorship 2011; 5 (1): 8-17. [DOI:10.1007/s11764-010-0153-7]
7. Sato A. Rationales for traditional medicines utilisation and its equity implications: the case of Ghana: The London School of Economics and Political Science (LSE); 2012.
8. Adams J, Andrews G, Barnes J, Broom A and Magin P. Traditional, complementary and integrative medicine: an international reader: Palgrave Macmillan; 2012. [DOI:10.1007/978-1-137-26559-3]
9. Qi Z and Kelley E. The WHO traditional medicine strategy 2014-2023: a perspective. Science 2014; 346 (6216): S5-S6.
10. Laleh H and, Vaferi R. History of evolution of traditional medicine to modern medicine in Gajar age. Journal Humanities Research University 2006; 16 (60): 131‐164. [In Persian].
11. Hysen P. Timeline of Graeco-Arabic Medicine. In: An introduction to Graeco-Arabic Medicine: Graeco-Arabic Medicine Society Inc; 2000 [cited 2014 7 Oct]. Available from: http://www.traditionalmedicine.net.au/graecarb.htm.
12. Elgood C. A medical history of Persia and the eastern caliphate: From the earliest times until the year AD 1932, Cambridge University Press; 2010. [DOI:10.1017/CBO9780511710766]
13. Zargaran A. Ancient Persian medical views on the heart and blood in the Sassanid era (224-637 AD). International J. Cardiology 2014; 172 (2): 307-12. [DOI:10.1016/j.ijcard.2014.01.035]
14. Bennison AK. The great caliphs: the golden age of the'Abbasid Empire: Yale University Press; 2014.
15. Browne EG. Islamic Medicine, 2002. ISBN 81-87570-19-9; 1921.
16. Dalfardi B, Daneshfard B and Nezhad GSM. Johannitius (809-873 AD), a medieval physician, translator and author. J. Medical Biography 2016; 24 (3): 328-30. [DOI:10.1177/0967772014532890]
17. Kelishadi R and Hatami H. Avicenna as the forerunner of preventive medicine: On the occasion of 1032nd birth anniversary of Avicenna (22 August 980). International J. Preventive Medicine 2012; 3 (8): 517.
18. Margaret M, Olszewski. Concepts of Cancer from Antiquity to the Nineteenth Century. UTMJ. 2010; 87: 181-6. [DOI:10.5015/utmj.v87i3.1252]
19. Edwards BK, Noone AM, Mariotto AB, Simard EP, Boscoe FP, Henley SJ, Jemal A, Cho H, Anderson RN, Kohler BA and Eheman CR. Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer 2014; 120: 1290-1314. [DOI:10.1002/cncr.28509]
20. Zhang G, Yang P, Guo P, Miele L, Sarkar FH, Wang Z and Zhou Q. Unraveling the mystery of cancer metabolism in the genesis of tumor-initiating cells and development of cancer. Biochim. Biophys. Acta. 2013; 1836: 49-59. [DOI:10.1016/j.bbcan.2013.03.001]
21. Emami SA, Sahebkar A, Tayarani-Najaran N and Tayarani-Najaran Z. Cancer and its treatment in main ancient books of Islamic Iranian traditional medicine (7th to 14th century AD). Iranian Red. Crescent. Medical J. 2012; 14 (12): 747. [DOI:10.5812/ircmj.4954]
22. Azam Khan M. Exir Azam, Vol.1. Tehran: Institute of Meical History, Islamic Medicine and Complementary Medicine; 2008. (in Persian)
23. Jorjani E. Zakhireye Kharazm Shahi (Treasure of Kharazm Shah), In: Moharreri MR, editor. Vol.2. Tehran: Iranian Medical Academy; 2001 (in Persian).
24. Naghibi F, Khalaj A and Moghadam MH. Cancer terminologies used in the medieval texts to the early modern Iranian traditional medicine (ITM). Journal of Research on History of Medicine 2014; 3 (2 May):63-70.
25. Razes. Al Havi [Liber Continent]. Beiruot: Ehyaol Toras al-Arabi Press; 2001. (in Arabic)
26. Kermani, Nafis-ebn-e-avaz, Sharholasbab-va-Alalamat, Qom, Jalaledin press, 1367, pp: 425-450. (In Arabic)
27. A. Ganon. Tehran, Iran: darotebao alijah aligholikhan; 1297, p: several pages. (in Arabic)
28. Shirbeigi L, Iranzadasl M, Mansouri P, Hejazi S and Aliasl J. Skin Aging Remedies in Traditional Persian Medicine. Journal of Skin and Stem Cell 2015; 2 (1): e30283. [DOI:10.17795/jssc3028]
29. Arzani MA. In: Teb-e-Akbari [Akbari's Medicine]. Ehya Teb e Tabiee O, editor. Tehran: Jalaleddin Press; 2008, pp. 641-2. (in Persian).
30. Moeini R, Gorji N, Rezaeizadeh H, Pasalar P, Nazem E and Kamalinejad M. Etiology and treatment of cancer; view point of Persian medicine. Medical History J. 2017; 9 (30): 55-82.
31. Tabatabaei SM and Tabatabaei SMA. Diagnosis and treatment of cancer in medical textbooks of ancient Iran. J. Medical Ethics and History of Medicine 2014; 7: 16.
32. Gorji N, Moeini R, Pasalar P, Rezaeizadeh H, Kamalinejad M and Nazem E. Cancer Biopsy in Ancient Persian Medicine: Do or Not to Do! Iranian J. Public Health 2015; 44 (10): 1440-1.
33. Siegel RL, Miller KD and Jemal A. Cancer statistics, 2017. CA: A Cancer J. for Clinicians 2017; 67 (1): 7-30. [DOI:10.3322/caac.21387]
34. Razi S, Rafiemanesh H, Ghoncheh M, Khani Y and Salehiniya H. Changing trends of types of skin cancer in Iran. Asian Pac. J. Cancer Prev. 2015; 16 (12): 4955-8. [DOI:10.7314/APJCP.2015.16.12.4955]
35. Kim RH and Armstrong AW. Nonmelanoma Skin Cancer Dermatol Clin. 2011; 30: 125-139. [DOI:10.1016/j.det.2011.08.008]
36. Koosha A, Farahbakhsh M, Hakimi S, Abdolahi L, Golzari M and Seyf Farshad M. Epidemiologic assessment of cancer disease in east Azerbaijan 2007. Med. J. Tabriz Univ. Med. Sci. 2010; 32: 74-79. (in Persian).
37. Woźniak A, Szyfter K, Szyfter W and Florek E. Head and neck cancer--history. Przeglad Lekarski. 2012; 69 (10): 1079-83.
38. Lai V, Cranwell W and Sinclair R. Epidemiology of skin cancer in the mature patient. Clin. Dermatol. 2018; 36(2): 167-76. [DOI:10.1016/j.clindermatol.2017.10.008]
39. Atarzadeh F, Heydari M, Sanaye MR and Amin G. Avicenna-A Pioneer in Dermatology. JAMA Dermatol. 2016; 152(11): 1257. [DOI:10.1001/jamadermatol.2016.0026]
40. Gandini S, Sera F, Cattaruzza MS, Pasquini P, Abeni D, Boyle P and et al. Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. European J. Cancer. 2005; 41 (1): 28-44. [DOI:10.1016/j.ejca.2004.10.015]
41. Constant E. Risk factors for cutaneous melanoma: A practical method of recognizing predisposed individuals. Plastic and Reconstructive Surgery 1989; 83 (4): 761. [DOI:10.1097/00006534-198904000-00085]
42. Katta R and Brown DN. Diet and skin cancer: The potential role of dietary antioxidants in nonmelanoma skin cancer prevention. J. Skin Cancer. 2015; 1:10. Article ID 893149 [DOI:10.1155/2015/893149]
43. Park MK, Li WQ, Qureshi AA and Cho E. Fat Intake and Risk of Skin Cancer in U.S. Adults. J. Cancer Epidemiology, Biomarkers & Prevention 2018; 27 (7): 776-82. [DOI:10.1158/1055-9965.EPI-17-0782]
44. Russak JE and Rigel DS. Risk factors for the development of primary cutaneous melanoma. Dermatologic Clinics 2012; 30 (3): 363-8. [DOI:10.1016/j.det.2012.05.002]
45. Curiel-Lewandrowski C, Chen SC and Swetter SM. Screening and Prevention Measures for Melanoma: Is There a Survival Advantage? Current Oncology Reports 2012; 14: 458-467. [DOI:10.1007/s11912-012-0256-6]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
